New drug for mesothelioma that has returned after prior treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called ivonescimab for people with pleural mesothelioma (a cancer of the lung lining) that has grown back after earlier immunotherapy and chemotherapy. The drug may help by blocking a protein that tumors use to hide from the immune system, possibly slowing or shrinking the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pleural mesothelioma confirmed by a biopsy (not just fluid samples).
- Your cancer has progressed after up to 2 lines of treatment, including immunotherapy (like nivolumab or pembrolizumab) and chemotherapy.
- You have measurable disease on a CT scan and are in generally good health (ECOG performance status 0 or 1).
- You are at least 18 years old, have not lost more than 10% of your body weight in the last 3 months, and have adequate kidney, liver, and blood function.
- You must provide tissue samples from previous biopsies for central review.
- You have not been treated with bevacizumab (or similar anti-angiogenic drugs) except as part of a specific combination, and you have had at least 21 days since your last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of four medicines (two newer immune-boosting drugs, a blood vessel-blocking drug, and chemotherapy) to treat advanced mesothelioma—a serious lung cancer caused by asbestos exposure. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests an immunotherapy drug for people with stage 3 lung cancer that hasn't been treated yet. It's for those whose tumors don't have certain genetic changes and who have not had prior cancer treatment.
Hear when a new Pleural Mesotheliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.